A Story1, S Murad, W Roberts, M Verheyen, A C Hayward. 1. Tuberculosis Section, Respiratory Diseases Department, Health Protection Agency Centre for Infections, London NW9 5EQ, UK. alistair.story@hpa.org.uk
Abstract
BACKGROUND: The control of tuberculosis (TB) is founded on early case detection and complete treatment of disease. In the UK, TB is concentrated in subgroups of the population in large urban centres. The impact of homelessness, imprisonment and problem drug use on TB control in London is reviewed. METHODS: A cohort study was undertaken of all patients with TB in Greater London to determine the point prevalence of disease in different groups and to examine risk factors for smear positivity, drug resistance, treatment adherence, loss to follow-up and use of directly observed therapy (DOT). RESULTS: Data were collected on 97% (1941/1995) of eligible patients. The overall prevalence of TB was 27 per 100,000. An extremely high prevalence of TB was seen in homeless people (788/100,000), problem drug users (354/100,000) and prisoners (208/100,000). Multivariate analysis showed that problem drug use was associated with smear positive disease (OR 2.2, p<0.001), being part of a known outbreak of drug resistant TB (OR 3.5, p = 0.001) and loss to follow-up (OR 2.7, p<0.001). Imprisonment was associated with being part of the outbreak (OR 10.3, p<0.001) and poor adherence (OR 3.9, p<0.001). Homelessness was associated with infectious TB (OR 1.6, p = 0.05), multidrug resistance (OR 2.1, p = 0.03), poor adherence (OR 2.5, p<0.001) and loss to follow-up (OR 3.8, p<0.001). In London, homeless people, prisoners and problem drug users collectively comprise 17% of TB cases, 44% of smear positive drug resistant cases, 38% of poorly compliant cases and 44% of cases lost to follow-up. 15% of these patients start treatment on DOT but 46% end up on DOT. CONCLUSIONS: High levels of infectious and drug resistant disease, poor adherence and loss to follow-up care indicate that TB is not effectively controlled among homeless people, prisoners and problem drug users in London.
BACKGROUND: The control of tuberculosis (TB) is founded on early case detection and complete treatment of disease. In the UK, TB is concentrated in subgroups of the population in large urban centres. The impact of homelessness, imprisonment and problem drug use on TB control in London is reviewed. METHODS: A cohort study was undertaken of all patients with TB in Greater London to determine the point prevalence of disease in different groups and to examine risk factors for smear positivity, drug resistance, treatment adherence, loss to follow-up and use of directly observed therapy (DOT). RESULTS: Data were collected on 97% (1941/1995) of eligible patients. The overall prevalence of TB was 27 per 100,000. An extremely high prevalence of TB was seen in homeless people (788/100,000), problem drug users (354/100,000) and prisoners (208/100,000). Multivariate analysis showed that problem drug use was associated with smear positive disease (OR 2.2, p<0.001), being part of a known outbreak of drug resistant TB (OR 3.5, p = 0.001) and loss to follow-up (OR 2.7, p<0.001). Imprisonment was associated with being part of the outbreak (OR 10.3, p<0.001) and poor adherence (OR 3.9, p<0.001). Homelessness was associated with infectious TB (OR 1.6, p = 0.05), multidrug resistance (OR 2.1, p = 0.03), poor adherence (OR 2.5, p<0.001) and loss to follow-up (OR 3.8, p<0.001). In London, homeless people, prisoners and problem drug users collectively comprise 17% of TB cases, 44% of smear positive drug resistant cases, 38% of poorly compliant cases and 44% of cases lost to follow-up. 15% of these patients start treatment on DOT but 46% end up on DOT. CONCLUSIONS: High levels of infectious and drug resistant disease, poor adherence and loss to follow-up care indicate that TB is not effectively controlled among homeless people, prisoners and problem drug users in London.
Authors: M C Ruddy; A P Davies; M D Yates; S Yates; S Balasegaram; Y Drabu; B Patel; S Lozewicz; S Sen; M Bahl; E James; M Lipman; G Duckworth; J M Watson; M Piper; F A Drobniewski; H Maguire Journal: Thorax Date: 2004-04 Impact factor: 9.139
Authors: F Chaves; F Dronda; M D Cave; M Alonso-Sanz; A Gonzalez-Lopez; K D Eisenach; A Ortega; L Lopez-Cubero; I Fernandez-Martin; S Catalan; J H Bates Journal: Am J Respir Crit Care Med Date: 1997-02 Impact factor: 21.405
Authors: M Gabriela M Gomes; Ricardo Aguas; João S Lopes; Marta C Nunes; Carlota Rebelo; Paula Rodrigues; Claudio J Struchiner Journal: Proc Biol Sci Date: 2012-02-22 Impact factor: 5.349
Authors: Michelle E Kruijshaar; John M Watson; Francis Drobniewski; Charlotte Anderson; Timothy J Brown; John G Magee; E Grace Smith; Alistair Story; Ibrahim Abubakar Journal: BMJ Date: 2008-05-01
Authors: Jürgen Rehm; Andriy V Samokhvalov; Manuela G Neuman; Robin Room; Charles Parry; Knut Lönnroth; Jayadeep Patra; Vladimir Poznyak; Svetlana Popova Journal: BMC Public Health Date: 2009-12-05 Impact factor: 3.295
Authors: Richard S Garfein; Rafael Laniado-Laborin; Timothy C Rodwell; Remedios Lozada; Robert Deiss; Jose Luis Burgos; Jazmine Cuevas-Mota; Paris Cerecer; Kathleen Moser; Maria Luisa Volker; Steffanie A Strathdee Journal: Emerg Infect Dis Date: 2010-05 Impact factor: 6.883